Drug Development

Potential Anti-Tuberculosis Compound Reported

Published in TB and Outbreaks Week, September 30th, 1996

PathoGenesis Corp., Seattle, Washington, scientists report on an antibiotic that has shown potent activity against Mycobacterium tuberculosis, the bacterium which causes tuberculosis (TB), including a battery of multidrug resistant strains.

PathoGenesis' research team reported in a series of papers at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting, held in New Orleans, Louisiana, September 15-18, 1996, that PA-824, a nitroimidazopyran compound, proved to be as active as the drug isoniazid (the standard form of TB therapy) in both test tube and in animal models of infection.

Most significantly,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1996-09-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry